Recombinant Human Angiotensin-converting Enzyme 2 (rhACE2) as a Treatment for Patients With COVID-19
Status:
Completed
Trial end date:
2020-12-26
Target enrollment:
Participant gender:
Summary
Recombinant human angotensin-converting enzyme 2 (rhACE2) as a treatment for patients with
COVID-19 to block viral entry and decrease viral replication.